ATE399162T1 - Flavon derivate als inhibitoren von cyclin- abhängigen kinasen - Google Patents

Flavon derivate als inhibitoren von cyclin- abhängigen kinasen

Info

Publication number
ATE399162T1
ATE399162T1 AT03753911T AT03753911T ATE399162T1 AT E399162 T1 ATE399162 T1 AT E399162T1 AT 03753911 T AT03753911 T AT 03753911T AT 03753911 T AT03753911 T AT 03753911T AT E399162 T1 ATE399162 T1 AT E399162T1
Authority
AT
Austria
Prior art keywords
cyclin
inhibitors
dependent kinases
flavone derivatives
flavone
Prior art date
Application number
AT03753911T
Other languages
English (en)
Inventor
Bansi Lal
Kalpana Joshi
Sanjeev Kulkarni
Malcolm Mascarenhas
Shrikant Kamble
Maggie Rathos
Rajendrakumar Joshi
Original Assignee
Nicholas Piramal India Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicholas Piramal India Ltd filed Critical Nicholas Piramal India Ltd
Application granted granted Critical
Publication of ATE399162T1 publication Critical patent/ATE399162T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT03753911T 2002-07-08 2003-07-07 Flavon derivate als inhibitoren von cyclin- abhängigen kinasen ATE399162T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN616MU2002 2002-07-08

Publications (1)

Publication Number Publication Date
ATE399162T1 true ATE399162T1 (de) 2008-07-15

Family

ID=30012269

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03753911T ATE399162T1 (de) 2002-07-08 2003-07-07 Flavon derivate als inhibitoren von cyclin- abhängigen kinasen

Country Status (20)

Country Link
EP (1) EP1556375B1 (de)
JP (1) JP4860148B2 (de)
KR (1) KR100991920B1 (de)
CN (1) CN1668613B (de)
AR (1) AR041184A1 (de)
AT (1) ATE399162T1 (de)
AU (1) AU2003272070B2 (de)
BR (1) BR0312633A (de)
CA (1) CA2492130C (de)
DE (1) DE60321808D1 (de)
DK (1) DK1556375T3 (de)
ES (1) ES2309338T3 (de)
IL (1) IL166153A (de)
MX (1) MXPA05000388A (de)
NZ (1) NZ537518A (de)
PT (1) PT1556375E (de)
RU (1) RU2334746C2 (de)
TW (1) TWI331034B (de)
WO (1) WO2004004632A2 (de)
ZA (1) ZA200500138B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7915301B2 (en) 2002-07-08 2011-03-29 Piramal Life Science Limited Inhibitors of cyclin dependent kinases and their use
KR101209397B1 (ko) * 2006-06-21 2012-12-06 피라말 라이프 사이언시스 리미티드 증식성 질환 치료용 광학이성적으로 순수한, 증식성 질환 치료용 플라본 유도체 및 이의 제조방법
RU2404965C2 (ru) * 2006-07-07 2010-11-27 Пирамал Лайф Сайнсиз Лимитед Способ энантиоселективного синтеза промежуточных соединений, используемых при получении пирролидинов, замещенных флавонами
CA2658215C (en) 2006-07-07 2013-08-27 Piramal Life Sciences Limited An enantioselective synthesis of pyrrolidines-substituted flavones
RU2438664C2 (ru) * 2007-05-15 2012-01-10 Пирамал Лайф Сайнсиз Лимитед Синергическая фармацевтическая комбинация для лечения рака
CA2687204C (en) * 2007-05-15 2015-11-24 Piramal Life Sciences Limited A synergistic pharmaceutical combination for the treatment of cancer
CN101333205A (zh) * 2008-07-10 2008-12-31 大连理工大学 周期素依赖蛋白激酶抑制剂黄芩素哌嗪衍生物及其制法
TWI461194B (zh) 2009-05-05 2014-11-21 Piramal Entpr Ltd 吡咯啶取代黃酮作為輻射致敏劑
CN102438452B (zh) * 2009-05-08 2015-02-25 乔治亚州大学研究基金会 包含cdk抑制剂的化合物和组合物以及用于癌症治疗的方法
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
MX2012009830A (es) * 2010-02-26 2013-02-11 Piramal Entpr Ltd Flavonas sustituidas de pirrolidina para el tratamiento de desordenes inflamatorios.
ES2640474T3 (es) 2010-11-18 2017-11-03 Ischemix Llc Compuestos lipoílicos y su uso para el tratamiento de la lesión isquémica
WO2012069972A1 (en) 2010-11-19 2012-05-31 Piramal Life Sciences Limited A pharmaceutical combination for the treatment of breast cancer
BR112013012313A2 (pt) * 2010-11-19 2019-09-24 Piramal Enterprises Limited combinação farmacêutica de paclitaxel e um inibidor de cdk
WO2012123889A1 (en) 2011-03-14 2012-09-20 Piramal Healthcare Limited A synergistic pharmaceutical combination for the treatment of pancreatic cancer
US8530470B2 (en) * 2011-04-13 2013-09-10 Astrazeneca Ab Chromenone derivatives
TW201300105A (zh) 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
AU2012274990A1 (en) 2011-06-24 2014-02-06 Piramal Enterprises Limited Compounds for the treatment of cancers associated with human papillomavirus
TW201338774A (zh) 2012-01-13 2013-10-01 Piramal Entpr Ltd 口腔粘膜炎預防或治療化合物
WO2014049515A1 (en) * 2012-09-25 2014-04-03 Piramal Enterprises Limited Pyrrolidine substituted flavones for treatment of renal cystic diseases
TWI839690B (zh) 2013-07-12 2024-04-21 印度商皮拉馬爾企業有限公司 治療黑色素瘤的藥物組合的用途
EP3148532B1 (de) 2014-05-28 2021-03-03 Piramal Enterprises Limited Pharmazeutische kombination, die einen cdk-inhibitor und einen thioredoxin-reduktase-inhibitor enthält, zur behandlung von krebs
CN107922360B (zh) * 2015-06-23 2021-05-25 科思创德国股份有限公司 取代的三嗪及其制造方法
IL295472B2 (en) 2016-03-28 2024-10-01 Presage Biosciences Inc Pharmaceutical combinations for the treatment of cancer
CN109843297A (zh) 2016-10-20 2019-06-04 辉瑞大药厂 治疗pah的抗增殖剂
EP3615023B1 (de) 2017-04-25 2023-06-21 Ischemix LLC Lipoyl-glu-ala zur behandlung der neurodegenerativen verletzung
CN107573270B (zh) * 2017-09-29 2019-11-29 河南师范大学 一种α-甲酰基吡咯烷类化合物的合成方法
EP3866929A1 (de) 2018-10-19 2021-08-25 F. Hoffmann-La Roche AG Chromen-4-on-derivate zur behandlung und prophylaxe von hepatitis-b-viruserkranungen
CN110028475B (zh) * 2019-05-13 2022-07-01 中国药科大学 基于苯并吡喃结构的新型cdk9抑制剂、其制备方法及应用
US12478621B2 (en) 2019-11-28 2025-11-25 Deutsches Krebsforschungszentrum Substituted aminoquinolones as dgkalpha inhibitors for immune activation
AR121719A1 (es) 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
CA3217937A1 (en) 2021-05-03 2022-11-10 Erin Danielle ANDERSON Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
MX2023013987A (es) 2021-05-27 2024-02-12 Petra Pharma Corp Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento contra el cáncer.
CN113549044B (zh) * 2021-07-23 2024-01-23 中国药科大学 8-氮杂环取代色酮类衍生物及其制备方法与制药用途
TW202329930A (zh) 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3836676A1 (de) * 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
HUT72741A (en) * 1992-12-19 1996-05-28 Alkaloida Vegyeszeti Gyar Method for producing benzopyrane derivatives and pharmaceutical compositions containing them
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5849733A (en) * 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
JP2003531899A (ja) * 2000-05-03 2003-10-28 エルジー ライフ サイエンス リミテッド 3−ヒドロキシクロメン−4−オン構造を有するcdk阻害剤

Also Published As

Publication number Publication date
ZA200500138B (en) 2006-02-22
CA2492130C (en) 2011-09-06
TWI331034B (en) 2010-10-01
DK1556375T3 (da) 2008-11-03
JP2006502109A (ja) 2006-01-19
MXPA05000388A (es) 2005-09-30
PT1556375E (pt) 2008-10-03
BR0312633A (pt) 2005-07-19
ES2309338T3 (es) 2008-12-16
NZ537518A (en) 2008-02-29
WO2004004632A8 (en) 2005-03-24
EP1556375A2 (de) 2005-07-27
EP1556375B1 (de) 2008-06-25
KR20050017110A (ko) 2005-02-21
RU2334746C2 (ru) 2008-09-27
TW200406202A (en) 2004-05-01
WO2004004632A2 (en) 2004-01-15
WO2004004632A3 (en) 2004-09-16
RU2005102939A (ru) 2005-09-10
DE60321808D1 (de) 2008-08-07
CA2492130A1 (en) 2004-01-15
AR041184A1 (es) 2005-05-04
AU2003272070A1 (en) 2004-01-23
KR100991920B1 (ko) 2010-11-04
CN1668613A (zh) 2005-09-14
IL166153A (en) 2009-11-18
AU2003272070B2 (en) 2009-02-26
JP4860148B2 (ja) 2012-01-25
IL166153A0 (en) 2006-01-15
CN1668613B (zh) 2012-07-04

Similar Documents

Publication Publication Date Title
DE60321808D1 (de) Flavon derivate als inhibitoren von cyclin-abhängigen kinasen
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
NO20045220L (no) Heterocykliske inhibitorer for kinaser
ATE370137T1 (de) 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE416171T1 (de) 2-hydroxy-3-heteroarylindole derivate als gsk3 inhibitoren
NO20043158L (no) Substituerte kinazolinderivater som inhibitorer av aurorakinaser
DE60309848D1 (de) Purinderivate als kinaseinhibitoren
DE602005025733D1 (de) Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
NO20050636L (no) Inhibitorer av tyrosinkinaser
IL230659A (en) Calicheamicin derivative-carrier conjugates
ATE413404T1 (de) Triazolopyrimidin derivate als inhibitoren von glycogen synthase kinase-3
ATE375336T1 (de) Triazolderivate als inhibitoren von11-beta- hydroxysteroid-dehydrogenase-1
ATE369356T1 (de) Pyridazinon-derivate als cdk2-hemmer
DE60305061D1 (de) 2-pyridonderivate als inhibitoren von neutrophiler elastase
NO20050072L (no) Nye inhibitorer av kinaser
ATE426599T1 (de) Thiazolylpiperidin derivate als mtp inhibitoren
EE200300459A (et) Uued spirotritsüklilised derivaadid ja nende kasutamine fosfodiesteraas-7 inhibiitoritena
CY2011016I2 (el) Λακταμουχες ενωσεις και παραγωγα αυτων ως αναστολεις του παραγοντα χα
ATE386730T1 (de) Phenylpiperazinderivate als serotonin wiederaufnahmehemmer
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
ATE393159T1 (de) Heterobicyclische pyrazolderivate als kinaseinhibitoren
ATE382048T1 (de) Pyrazolopyrimdine als hemmstoffe cyclin abhängiger kinasen
EP1660436A4 (de) Cathepsininhibitoren
DE60231897D1 (de) Triazol derivate als cyclooxygenase inhibitoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1556375

Country of ref document: EP

EEIH Change in the person of patent owner